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Synergistic interaction between lipid-loading and
doxorubicin exposure in Huh7 hepatoma cells
results in enhanced cytotoxicity and cellular
oxidative stress: implications for acute and
chronic care of obese cancer patients†
S. AlGhamdi, V. Leoncikas, K. E. Plant and N. J. Plant*
There has been a dramatic increase in the number of clinically obese individuals in the last twenty years.
This has resulted in an increasingly common scenario where obese individuals are treated for other dis-
eases, including cancer. Here, we examine interactions between lipid-induced steatosis and doxorubicin
treatment in the human hepatoma cell line Huh7. The response of cells to either doxorubicin, lipid-
loading or a combination were examined at the global level by DNA microarray, and for speciﬁc endpoints
of cytotoxicity, lipid-loading, reactive oxygen species, anti-oxidant response systems, and apoptosis. Both
doxorubicin and lipid-loading caused a signiﬁcant accumulation of lipid within Huh7 cells, with the com-
bination resulting in an additive accumulation. In contrast, cytotoxicity was synergistic for the combination
compared to the individual components, suggesting an enhanced sensitivity of lipid-loaded cells to the
acute hepatotoxic eﬀects of doxorubicin. We demonstrate that a synergistic increase in reactive oxygen
species and deregulation of protective anti-oxidant systems, most notably metallothionein expression,
underlies this eﬀect. Transcriptome analysis conﬁrms synergistic changes at the global level, and is con-
sistent with enhanced pro-inﬂammatory signalling in steatotic cells challenged with doxorubicin. Such
eﬀects are consistent with a potentiation of progression along the fatty liver disease spectrum. This
suggests that treatment of obese individuals with doxorubicin may increase the risk of both acute (i.e.
hepatotoxicity) and chronic (i.e. progress of fatty liver disease) adverse eﬀects. This work highlights the
need for more study in the growing therapeutic area to develop risk mitigation strategies.
Introduction
The incidence of breast cancer in women has remained stub-
bornly high, aﬀecting approximately one in eight women in
the Western world during their lifetimes.1 In contrast, the inci-
dence of obesity and its related morbidities has rapidly
increased over the past twenty years.2 One consequence of this
is the increased probability of treating obese individuals for
breast cancer, especially given the positive correlation between
obesity and breast cancer in post-menopausal women.3 An
important co-morbidity associated with obesity is the spec-
trum of fatty liver diseases, ranging from simple steatosis,
through steatohepatitis to cirrhosis and/or hepatocarcino-
genesis. The molecular underpinnings of each of these conditions
is still not fully elucidated, nor the rationale for progression
through the disease spectrum fully understood.2 However,
what is clear is that the liver undergoes a number of metabolic
changes as it progresses through this spectrum, initially as an
adaptation to excess lipid, and then as a result of the develop-
ment of pathology. These changes alter the liver’s ability to
both maintain body homeostasis and to eﬃciently handle
therapeutic agents.4 An important question is how the impact
of breast cancer treatment with standard therapeutics alters in
individuals with fatty liver disease. Such impacts could include
an enhanced adverse eﬀect profile over both acute (e.g.
increased cytotoxicity against non-malignant tissues) or
chronic (e.g. increased progression through the fatty liver
disease spectrum) time periods. Given the increasing success
of chemotherapy, producing an ever-increasing pool of cancer
survivors who must live with the potential long-term conse-
quences of their chemotherapy, it is important to understand
these chronic eﬀects.5,6
Doxorubicin (Dox) is a member of the quinone-containing
anthracycline antibiotics, and due to its wide distribution
throughout the body it is eﬀective in the treatment of a
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c5tx00173k
Department of Biochemistry and Physiology, Faculty of Health and Medical Sciences,
University of Surrey, Guildford, Surrey GU2 7XH, UK. E-mail: N.Plant@Surrey.ac.uk
This journal is © The Royal Society of Chemistry 2015 Toxicol. Res., 2015, 4, 1479–1487 | 1479
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
A
ug
us
t 2
01
5.
 D
ow
nl
oa
de
d 
on
 2
9/
09
/2
01
7 
15
:0
0:
45
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e. View Article Online
View Journal  | View Issue
number of human cancers, including breast cancer.7–9 Due to
the non-targeted nature of doxorubicin’s mode of action,
adverse side eﬀects are diverse, most notably cardiotoxicity
and to a lesser extent hepatotoxicity.10,11 At present, the pub-
lished literature regarding interactions between doxorubicin
and fatty acids are conflicting. For example, both adverse12,13
and protective14,15 interactions between doxorubicin and
omega-3 fatty acids have been reported. In addition, Magnolia
seed extract, which is rich in linoleate, oleate and palmitate
has been reported to ameliorate doxorubicin cardiomyocyte
toxicity in vitro.16 Finally, epidemiological studies suggest that
doxorubicin may promote progression through the fatty liver
disease spectrum.17,18 This contradictory evidence between
studies suggests a complex interaction that may be context
(e.g. cell type/species/concentration) dependent, and thus
requires further study.
In this work we confirm that both free fatty acids and doxo-
rubicin cause lipid-loading (steatotic phenotype) in human
hepatoma cells, and that their combination results in an addi-
tive eﬀect on intracellular lipid accumulation. In contrast,
cytotoxicity is synergistic, as is the increase in reactive oxygen
species. Such alterations, we believe, are consistent with
enhanced sensitivity of obese individuals to the acute adverse
eﬀects of doxorubicin, more specifically hepatotoxicity. In
addition, the observed synergistic increase in oxidative stress
and pro-inflammatory signalling is likely to potentiate tran-
sition along the fatty liver disease spectrum, creating an
increased health burden for those who survive their cancer
treatment.
Materials and methods
Materials
Doxorubicin, fatty acid free BSA, oleate, palmitate and stauro-
sporine were all purchased from Sigma Aldrich (Poole, UK).
Primary antibodies were purchased from Santa Cruz Biotech-
nology (TX, USA) for Metallothionein (FL-61), while secondary
antibodies and Cell Tag 700 Stain were purchased from Li-Cor
Biosciences (Cambridge, UK).
Cell culture
The human hepatoma cell line Huh719 was a kind gift from
Steve Hood (GlaxoSmithKline, Ware, UK) and were cultured in
Dulbecco’s Modified Eagle Medium with 2 mM L-glutamine,
4.5 g L−1 glucose, 100 units per mL1 each penicillin and
streptomycin, and 10% foetal bovine serum (FBS), at 37 °C and
5% CO2. Huh7 cells were seeded at 1 × 10
4 cell per cm2 into
appropriate vessels 24 h prior to treatment. For lipid-loading
of cells, palmitate and oleate were first dissolved in DMSO and
conjugated to fatty acid free BSA at the required concentration
as described by Wang et al.20 Cells were exposed to the BSA-
conjugated lipid mixture for 24 h prior to subsequent experi-
ments to allow lipid-loading to occur.
Viability assay
Cell viability was assessed by the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) assay, as previously
described.21 Briefly, Huh7 cells were exposed to lipid and/or
doxorubicin for the required time; during the final 180 min of
incubation, 0.5 mg mL−1 MTT was added. At the end of the
incubation period, the resultant formazan salt was dissolved
in DMSO and its absorbance measured at 540 nm. Results are
expressed as a percentage of vehicle control; each data point
represents the mean of a minimum of three independent
experiments of 6 wells per experiment, with error bars repre-
senting the standard error of the mean (SEM). Combination
index was calculated using Compusyn.22
Intracellular lipid analysis
Intracellular lipid content was determined fluorometrically
based on staining with Nile Red. Following exposure of Huh7
cells to lipid and/or doxorubicin, cells were processed by two
methods. For microscopy, cells were washed and then fixed
with 3.7% para-formaldehyde for 10 minutes. Next, 1 µM Nile
Red was added and cells incubated at room temperature
for 15 min in the dark. Images were acquired using a
Nikon Eclipse TS100 inverted fluorescence microscope (λex
510–560 nm, λem 590 nm). For quantitation of intracellular
lipid, cells were recovered from the flasks, stained with 1 µM
Nile Red as before and lipid content quantified using a Mole-
cular Devices SpectraMax Gemini XS fluorescence spectro-
photometer (CA, US) (λex 485 nm, λem 535 nm). These values
were exported to Excel, background fluorescence (medium
only) removed, and then normalised for cellular protein. Lipid
content was expressed as relative fluorescence units per mg
protein.
Intracellular reactive oxygen species analysis
Intracellular ROS levels were assessed using the ROS-Glo™
H2O2 assay from Promega (Southampton, UK) following the
manufacturer’s instructions. Briefly, Huh7 cells were exposed
to lipid and/or doxorubicin as described previously; during the
final 6 hours of incubation, 25 μM H2O2 substrate solution was
added to the cells. At the end of incubation time, ROS-Glo
Detection solution was added, incubated for 20 minutes and
then luminescence was measured using a BMG LABTECH
FLUOstar Omega plate reader (Ortenberg, Germany).
Caspase activity assay
Caspase 3/7 activity was measured using the Caspase-Glo
3/7assay kit (Promega, UK) as previously reported.23 Briefly,
Huh7 cells were exposed to lipid and/or doxorubicin as
required. Next, Caspase-Glo reagent was added, mixed, and
incubated at room temperature for one hour. Luminescence
was measured using a BMG LABTECH FLUOstar Omega plate
reader (Ortenberg, Germany).
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Transcriptomic analysis
Huh7 cells (naïve or pre-loaded with 300 µM FFA mixture for
24 hours) were exposed to doxorubicin for 4 or 12 hours, and
then total RNA was extracted from cells using the RNeasy Plus
Mini Kit (QIAGEN-UK) according to manufacturer’s instruc-
tions. RNA samples were sent to the Central Biotechnology
Services (Cardiﬀ University, UK), for quality control, synthesis
of biotin-labeled cRNA, and hybridisation against Illumina
Human-HT12 (Illumina, Inc., Hayward, CA) chips. Washed
chips were scanned using a Bead Station 500× (Illumina) and
the signal intensities quantified with BeadStudio (Illumina).
Analysis of array output files was performed within the Bio-
conductor R suite:24 data pre-processing was performed using
the beadarray and illuminaHumanv4.db packages;25 diﬀeren-
tial gene expression analysis was undertaken using the limma
package.26 Microarray data files are available through Array-
Express (https://www.ebi.ac.uk/arrayexpress/), accession number
E-MTAB-3523. Functional clustering analysis was undertaken
using the DAVID suite to identify statistically over-represented
Gene Ontology (GO) terms.27 Network interactions were visual-
ised using hive plots generated by the R package HiveR.
Protein analysis
Cells were exposed to lipid and/or doxorubicin as required. At
the end of incubation period, cells were fixed in 3.7% para-
formaldehyde and permeabilised with 0.1% Triton X-100.
Non-specific binding was blocked with Odyssey Blocking
buﬀer for 1.5 h at room temperature with gentle shaking.
Primary antibodies (1 : 100) were incubated overnight at 4 °C
with shaking, followed by IRDye 800 CW secondary anti rabbit
antibody (1 : 600) and 0.2 μM Cell Tag 700 Stain for 1 h at
room temperature with gentle shaking. Quantification was
undertaken with an Odyssey Imaging System (LI-COR Bio-
sciences) at 800 nm for IRDye 800 CW and 700 nm for Cell Tag
700 Stain.
Statistical analysis
Statistical analysis was undertaken using GraphPad Prism
v6.01 (GraphPad Software Inc, La Jolla, USA). Datasets were
compared through either a one-way ANOVA with Tukey’s mul-
tiple comparison test or a two-way ANOVA with Sidak’s mulit-
ple comparison test, as appropriate. The level of statistical
significance was set a priori at p < 0.05.
Results and discussion
Doxorubicin and FFA-mediated lipid-loading elicit a
synergistic increase in cytotoxicity
To examine the potential for a steatotic phenotype to alter the
acute toxic liability associated with doxorubicin the
Huh7 human hepatoma cell line was employed. These cells
have previously been demonstrated to respond to a range of
chemical agents, and possess a transcriptomic and metabolo-
mic profile similar to in vivo hepatocytes.28 The impact of both
the C16 saturated fatty acid palmitate, and the C18 : 1 unsatu-
rated fatty acid oleate on Huh7 cell viability was examined.
These fatty acids were chosen as they represent the commonest
saturated and unsaturated fatty acids found in Western diets,
respectively.29 Oleate was non-toxic at all concentrations tested
(maximum 1 mM), while palmitate caused a concentration
dependent reduction in cell viability that reached statistical
significance at 150 µM (Fig. 1a). As these fatty acids are rarely
found in the diet in isolation, the impact of a free fatty acid
(FFA) mixture was examined. As expected, toxicity of this FFA
mixture was predominantly driven by the toxicity of palmitate,
with all mixtures containing greater than 200 µM palmitate
causing significant toxicity (data not shown). An FFA mixture
of 300 µM (2 : 1 v/v oleate : palmitate) caused no significant
toxicity (Fig. 1a), and is consistent with clinical data in the
Western population where no-fasting serum levels of palmitate
and oleate are reported as approximately 140 µM and 90 µM,
respectively.30 This FFA mixture was used in all subsequent
studies.
Exposure of cells to doxorubicin caused a concentration-
dependent toxicity, with an IC50 value of 17 ± 4.6 µM in naïve
hepatocytes, consistent with previous observations (Fig. 1b;
ref. 31). Cells that have been lipid-loaded with the 300 µM FFA
mixture for 24 h prior to doxorubicin exposure showed an
Fig. 1 Synergistic cytotoxicity between doxorubicin and lipid-loading in
Huh7 cells. (A) Huh7 cells were exposed to varying concentrations of
fatty acids or a 300 µM FFA mixture (2 : 1 v/v oleate : palimitate) for 24 h
and then cell viability measured by MTT assay. Huh7 cells, either naïve
(black bars) or pre-loaded with 300 µM FFA mixture for 24 h (open bars),
were exposed to varying concentrations of fatty acids, or doxorubicin
for 24 h, and then cell viability (B) or (C) caspase 3/7 activity was
measured. A combination index was calculated to examine potential
interactions between the FFA mixture and doxorubicin. Each data point
represents the mean of three independent experiments. Error bars rep-
resent the standard error of the mean (SEM). * = p < 0.05, ** = p < 0.01,
*** = p < 0.001 compared to vehicle control or the indicated
comparison.
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enhanced sensitivity, with an IC50 value of 3.6 ± 5.4 µM
(Fig. 1b). This result is not specific to the FFA mixture, as pre-
loading with 1 mM oleate also caused a significant increase in
sensitivity, producing an IC50 value of 6.8 ± 4.5 µM (data not
shown).
In both cases, the observed toxicity from the combination
was synergistic compared to the individual treatments,
with maximal combination indexes of 0.2 and 0.1 for
doxorubicin : FFA mixture and doxorubicin : oleate, respectively
(Fig. 1b).
Previous data demonstrates that doxorubicin can induce
apoptosis in many cell lines, including Huh7 cells,32 and we
thus examined the activity of executioner caspases in our
system. As can be seen in Fig. 1c, both lipid loading and doxo-
rubicin elicited a statistically significant increase in caspase-3/7
activity. However, the combination of doxorubicin treatment
of 300 µM FFA lipid-loaded cells demonstrated a clear synergy
when compared to the individual treatments alone.
This suggests that steatotic hepatocytes are significantly
more sensitive to the cytotoxic eﬀects of doxorubicin than
naïve hepatocytes, with lipid-loading acting to prime the cells
against any subsequent perturbations.
Both lipid loading and doxorubicin have been reported to
induce intracellular lipid accumulation (steatosis) in a number
of experimental systems.33–36 To confirm that this was the case
in our model system, the extent of lipid accumulation was also
assessed under these conditions. Treatment of cells with 300
µM FFA or 3.6 µM doxorubicin resulted in significant intra-
cellular lipid accumulation (Fig. 2a), which was confirmed to
be in the form of lipid droplets (Fig. 2b). Lipid accumulation
was approximately 3.4-fold and 4.7-fold above control for 300
µM FFA and 3.6 µM doxorubicin, respectively. Treatment of
300 µM FFA lipid-loaded hepatocytes with 3.6 µM doxorubicin
resulted in an approximate 10-fold increase in lipid levels
(Fig. 2), consistent with an additive eﬀect.
Current literature suggests that doxorubicin-mediated tox-
icity may be either ameliorated or potentiated by fatty acid
(pre)treatment.12–14,16 These data are sourced from a number
of cell backgrounds (e.g. renal, breast, cardiac), species (e.g.
human, rat, mouse) and protocols (including in vitro versus
in vivo measurement). As such, this contradictory data may
suggest that the interaction between doxorubicin and fatty
acids is context-dependent, meaning that it is important to
study responses in human liver models to best predict the
response in this organ in vivo.
The data presented here supports an adverse, synergistic
interaction between lipid-loading and doxorubicin in human
hepatocytes. This interaction could be the explained via either
a direct mechanistic interaction between doxorubicin and
FFAs, or an indirect action whereby, for example, lipid-loading
alters the intracellular concentration of doxorubicin. Robust
measurement of intracellular doxorubicin and lipid concen-
trations would be required to definitively answer this question,
but we do note that doxorubicin has been demonstrated to
inhibit palmitate uptake into cardiomyocytes.37 However, as
we observe both additive and synergistic eﬀects this would
support an interaction as opposed to a simple shift along the
concentration-response curve.
Transcriptomic analysis of the diﬀerential response of naïve
and lipid loaded hepatocytes to doxorubicin treatment
Having demonstrated that lipid-loaded hepatocytes were more
sensitive to the acute cytotoxic eﬀects of doxorubicin, we next
undertook a transcriptomic analysis to examine the molecular
mechanisms that may underlie this eﬀect. In addition, such a
study may help to predict genotype-phenotype relationships
that underpin the chronic response to doxorubicin of steatotic
hepatocytes.38,39 Huh7 cells (naïve or pre-loaded with 300 µM
FFA mixture for 24 h) were exposed to doxorubicin for 4 hours
or 12 hours and then their transcriptomes analysed. Two con-
centrations of doxorubicin were examined: 3.6 µM and 0.1 µM,
representing the previously determined IC50 value and a non-
steatotic level. In addition, these concentrations are consistent
with the clinical scenario: peak plasma concentrations are
typically 5–15 µM, with free doxorubicin concentrations in
the range 1–4 µM.40 Raw data files are deposited within
ArrayExpress (accesssion ID: E-MTAB-3523), and diﬀerentially
expressed genes (DEGs) provided as ESI.†
Lipid-loading with the 300 µM FFA mixture caused a signifi-
cant transcriptome change at the early and late time points,
eliciting 577 and 440 statistically significant alterations,
Fig. 2 Additive lipid-accumulation between doxorubicin and lipid-
loading in Huh7 cells. Huh7 cells, either naïve or pre-loaded with 300
µM FFA mixture (2 : 1 v/v oleate : palimitate) for 24 h, were exposed to
3.6 µM doxorubicin for 24 h. Intracellular lipid accumulation was
detected by Nile Red and (A) quantiﬁed or (B) visualised by ﬂuorescence
microscopy. For lipid quantitation, each data point represents the mean
of three independent experiments. Error bars represent the standard
error of the mean (SEM). * = p < 0.05.
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respectively (adjusted p-value <0.01). As expected, exposure of
naïve Huh7 cells to 0.1 µM doxorubicin elicited only minor
transcriptome changes, consistent with its minimal impact on
cellular phenotype. In contrast, 3.6 µM doxorubicin caused
578 and 535 significant transcript alterations following 4 and
12 hours exposure, respectively. Analysis of the transcriptomic
data revealed lipid loading and doxorubicin exposures caused
shared regulation of 35 and 152 genes following 4 h and 12 h
treatment, respectively. When compared to the total number of
genes altered, this represents a 45% overlap, which suggests a
highly conserved phenotypic core between these two distinct
treatments.
When the transcriptome perturbations elicited by the two
treatments were compared, 401/578 (69%, 95% CI 64–74%)
and 416/535 (78%, 95% CI 72–83%) changes were found to be
shared following 4 h and 12 h treatment, respectively. This
suggests a highly conserved core response to these two, quite
diﬀerent, perturbations.
Hive plots allow an unbiased analysis of the relationships
within a network.41 As nodes are mapped on, and positioned
within, an axis based upon structural properties, hive plots
demonstrate network characteristics in a reproducible and
unbiased manner. Fig. 3a provides hive plots for each con-
dition; axes represent diﬀerentially expressed genes (DEGs;
grey nodes), while DEGs common between treatments are
linked by arcs.
For 0.1 µM doxorubicin treatment (Fig. 3, top row), only
lipid-loading produced significant alterations in transcript
levels. For 3.6 µM doxorubicin treatment (Fig. 3, bottom row),
both doxorubicin treatment and lipid-loading produced DEGs
at both time points, with many of these perturbations being
shared (red arcs). As the position of a DEG node on an axis is
determined by its expression level, it is possible to see that the
level of diﬀerential expression caused by both treatments is
similar, with connecting arcs being concentric in nature.
We note that at the early time point of 4 h, the combination
treatment results in no DEGs, suggesting that the eﬀect of the
two treatments eﬀectively cancel out each other.
In contrast, following 12 h exposure to both 300 µM FFA
and doxorubicin we observe many DEGs, the majority of which
are common with doxorubicin or lipid-loading alone (green
and blue arcs, respectively). While, DEG fold changes were
consistent between the two treatments when given alone, com-
bination treatment results in significant alterations in the fold
change of many DEGs, as indicated by the non-concentric
nature of the connecting arcs (blue and green). The synergistic
nature of the transcript changes are also supported by the
maximal fold changes observed, as indicated by the length of
the axis: maximal fold change observed for 300 µM FFA or
3.6 µM doxorubicin alone are 6.0-fold and 6.2-fold, respecti-
vely, while this increases to 14.9-fold for the combination
treatment.
To explore the biological consequences of these transcrip-
tome alterations we used the DAVID tool to examine for over-
representation of gene ontology terms within the DEGs.
Biological process terms associated with lipid metabolism,
insulin signalling, proliferation, inflammation and drug
metabolism were identified following both 300 µM FFA and
doxorubicin treatment, and with combination treatment. Such
over-represented terms are consistent with the previously
reported biological eﬀects for these perturbations.42 For
example, after twelve hours exposure to the combination treat-
ment the expression of genes involved in lipid homeostasis
(e.g. acetyl CoA carboxylase, microsomal triglyceride transfer
protein, and sterol O-acyltransferease 2) were all significantly
down-regulated. In contrast, the expression of genes associated
with lipid biosynthesis (e.g. HMG-CoA2, fatty acid desaturase
1/2, fatty acid synthase) were all up-regulated. Such data are
consistent with a shift toward an increasing lipid load within
the cells, with lipid biosynthesis increasing at a greater
rate than lipid metabolism. In addition, a cellular response to
ROS-mediated damage can be seen through the modulation
of expression of genes associated with inflammation
(e.g. alpha2 macroglubulin, interleukin 8, leukotriene
A4 hydroxylase, and Factor 11 receptor), and, as highlighted in
Fig. 4, the metallothionein rescue response system (e.g.metallo-
thionein proteins, HAMP).
Enhanced acute toxicity of doxorubicin in lipid-loaded
hepatocytes is mediated through increased oxidative stress
Both doxorubicin and lipid-loading have been previously
associated with increased reactive oxygen species production
in various cell types, including liver cells.43 It is therefore
logical to hypothesise that oxidative stress is the mechanistic
underpinning for the observed synergistic toxicity between
Fig. 3 Transcriptomic analysis of Huh7 cells exposed to doxorubicin
and/or lipids reveals marked commonality in response. Huh7 cells,
either naïve or pre-loaded with 300 µM FFA mixture (2 : 1 v/v oleate :
palimitate) for 24 h, were exposed to 3.6 µM doxorubicin for 4 h or 12 h,
and then transcriptomes analysed by Illumina bead array. Diﬀerentially
expressed genes (DEGs) are presented as Hive plots: each axis rep-
resents and individual comparison, with DEGs presented as grey nodes,
with position along the axis determined by fold-change; where DEGs
are common between two axes, they are connected by an arc. DEGs
were determined from three independent treatments for each condition,
with an adjusted p-value <0.05 deemed signiﬁcant.
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these two treatments. To examine this hypothesis, we
measured the level of ROS in cells treated with lipids or doxo-
rubicin alone, or in combination. As shown in Fig. 4a both
doxorubicin and lipid-loading alone were capable of inducing
a significant increase in ROS within Huh7 cells in a time-
dependent manner, with peak ROS levels observed following
24 h of treatment. Importantly, the combination treatment
produced a significantly enhanced ROS level at all the time
points examined, greater than that expected through simple
eﬀect additivity. We have confirmed this synergistic interaction
using an alternate reporter dye, 2′,7′-dichlorodihydrofluore-
scein diacetate (DCF-DA), and present this data as ESI Fig. 1.†
The induction of intracellular ROS would be expected to
lead to a number of biological responses, with the aim of
returning the cell to homeostasis: consistent with this, tran-
scriptome analysis revealed an over-representation of GO-
terms associated with oxidative stress responses. To further
explore these changes, the individual transcript levels for all
oxidative stress response DEGs are presented in Fig. 4b. The
main DEGs identified were members of the metallothionein
family (MTs), glutathione peroxidase (GPX) and uncoupling
protein 2 (UCP2), but the behaviours were significantly
diﬀerent. For GPX and UCP2, 3.6 µM doxorubicin or 300 µM
FFA alone produced an up-regulation at 4 hours, which
reversed to a down-regulation at 12 hours. Up-regulation of
GPX has been previously reported the HepG2 hepatoma cell
line44 and in TR9-7 cells following doxorubicin exposure.45 In
contrast, members of the metallothionein protein family,
Fig. 4 Synergistic oxidative stress between doxorubicin and lipid-loading in Huh7 cells. Huh7 cells, either naïve or pre-loaded with 300 µM FFA
mixture (2 : 1 v/v oleate : palimitate) for 24 h, were exposed to the indicated concentration of doxorubicin for various times and then various
parameters measured: (A) ROS, (B) transcripts associated with oxidative stress response, and (C) metallothionein protein levels. Each data point
represents the mean of three independent experiments. Error bars represent the standard error of the mean (SEM) * = p < 0.05, ** = p < 0.01,
*** = p < 0.001.
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which are a complementary protective system in the mainten-
ance of ROS homeostasis within the cell46,47, show the
opposite behaviour: they are down-regulated at 4 hours and
up-regulated by 12 hours by the individual treatments. One
hypothesise is that activation of metallothionein proteins
may act to protect cells from ROS in the absence of glutathione
peroxidase, and hence the two systems demonstrate an inverse
relationship.
We note with interest that the combination of doxorubicin
treatment in previously lipid-loaded cells has an inverse
expression pattern when compared to both treatments alone.
Transcripts for MT are up-regulated at 4 h and down-regulated
by twelve hours, with GPX and UCP2 showing the opposite
pattern. We confirmed this diﬀerential regulation of MT
by doxorubicin in naïve and lipid-loaded cells levels through
in-cell westerns (Fig. 4c).
One possible explanation for the observed data is the comp-
lementary nature of the GPX and MT oxidant defence systems.
As depicted in Fig. 5, the response to a single perturbation (i.e.
doxorubicin or FFA) is an increase in intracellular ROS, which
in turn activates the GPX/MT defence mechanism. This adap-
tation allows return to homeostasis with minimal cell loss,
which will be via programmed cell death. However, in con-
ditions of multiple perturbations (i.e. doxorubicin and FFA-
induced steatosis), the level of intracellular ROS accumulation
are much higher, overwhelming the oxidative stress response
system and leading to increased levels of cytotoxicity.
In addition, as both necrotic and apoptotic cell death have
been associated with pro-inflammatory signalling in hepato-
cytes,48,49 this will potentiate an inflammatory response,
leading to progression through the fatty liver disease spec-
trum.2 Suchaproposedmechanism is consistwith the epidemio-
logical data supporting a positive association between
doxorubicin treatment and progression along the fatty liver
disease spectrum.17,18
Conclusions
Within Western society, obesity is now recognised as being a
health problem of epidemic proportions. Not only does this
raise serious issues with regard to the direct treatment of
obesity and its related morbidities, but it also means that
many therapeutics are now being used to treat an obese popu-
lation. Given that the majority of clinical trials specifically
exempt obese individuals, this means that many therapeutics
are being prescribed to patient populations in which they have
not been extensively tested. As such, it is important to consider
both the acute and chronic implications of such a treatment
scenario, and in particular in disease conditions such as
cancer where aggressive treatment regimens have led to
improved survivorship. We provide more data to confirm the
observation that obese individuals may be more sensitive to
the acute adverse eﬀects of drugs. As depicted in Fig. 5, our
data is consistent with a scenario where exposure alone to
doxorubicin or lipid-loading elicits steatosis plus accompany-
ing oxidative stress. In this case, the cell is able to mount an
eﬀective response and adapt to this steatotic phenotype
through enhanced expression of anti-oxidant defence mecha-
nisms. However, when the treatments are combined the addi-
tive eﬀect on intracellular lipid accumulation produces a
synergistic increase in oxidative stress, which we believe over-
whelms the cell. The adaptive response is muted, leading to
higher levels of cell death, including necrosis, resulting in an
inflammatory response in the local tissue (Fig. 5). Importantly,
this supports the notion that therapeutic agents such as doxo-
rubicin may synergise with pre-existing cellular steatosis to
generate a pro-oxidative, pro-inflammatory environment. Given
that inflammatory infiltration is a key determinant in pro-
gression from simple steatosis to the more complex (and less
benign) steatohepatitis,2 our data suggests that treatment of
obese patients with doxorubicin may act to progress individ-
uals through the fatty liver disease spectrum toward more
complex phenotypes with significant health and wellbeing
implications. This area requires significantly more research to
understand how such a paradigm translates to the clinic, and
to investigate treatment strategies to minimize such a
possibility.
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Fig. 5 Synergistic interactions between doxorubicin and lipid-loading
in hepatocytes. In naïve hepatocytes (left panel), exposure to either
doxorubicin or free fatty acids (FFA) results in steatosis and oxidative
stress. GPX/MT-mediated adaptation acts to reduce ROS levels, minimis-
ing the necessity for cell death through apoptosis. In steatotic hepato-
cytes (right panel), the combination of doxorubicin and FFA exposure
leads to additive lipid accumulation, and synergistic intracellular ROS
levels. This overwhelms the GPX/MT adaptive system, resulting in
increased cell death, release of pro-inﬂammatory signals and poten-
tiation through the fatty liver disease spectrum.
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